You have 9 free searches left this month | for more free features.

fluzoparib

Showing 1 - 24 of 24

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Relapsed Ovarian Cancer Trial in Hangzhou (Fluzoparib+Apatinib, Fluzoparib)

Recruiting
  • Relapsed Ovarian Cancer
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 25, 2021

Ovarian Cancer Trial in Tai'an (Bevacizumab, chemo, Fluzoparib)

Recruiting
  • Ovarian Cancer
  • Tai'an, Shandong, China
    The Second Affiliated Hospital of Shandong First Medical Univers
Dec 24, 2021

Metastatic Castration Resistant Prostate Cancer Trial in Shanghai (Fluzoparib, Enzalutamide OR abiraterone acetate With

Recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Fluzoparib
  • +3 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Dec 6, 2021

Renal Impairment Trial (Fluzoparib)

Not yet recruiting
  • Renal Impairment
  • Fluzoparib
  • (no location specified)
Aug 27, 2021

Renal Cell Carcinoma Trial in Nanjing (Fluzoparib)

Recruiting
  • Renal Cell Carcinoma
  • Fluzoparib
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Feb 19, 2022

Advanced Solid Tumor Trial in Changsha (Fluzoparib, Omeprazole)

Completed
  • Advanced Solid Tumor
  • Changsha, Hunan, China
    The third xiangya hospital Hospital,of central south university
Jul 28, 2022

High-risk Prostate Cancer, Neoadjuvant Therapy Trial in Shanghai (Abiraterone acetate, Fluzoparib, Prednisone)

Recruiting
  • High-risk Prostate Cancer
  • Neoadjuvant Therapy
  • Abiraterone acetate
  • +4 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 23, 2022

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Beijing (Fluzoparib; Apatinib, Fluzoparib, Placebo)

Active, not recruiting
  • Ovarian Cancer
  • +2 more
  • Fluzoparib; Apatinib
  • +2 more
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 22, 2022

Ovarian Cancer Trial (Fluzoparib, QL1101)

Not yet recruiting
  • Ovarian Cancer
  • Fluzoparib
  • QL1101
  • (no location specified)
Oct 18, 2022

NSCLC Trial in Tianjin (biological, drug, radiation)

Recruiting
  • Non-small Cell Lung Cancer
  • Camrelizumab
  • +5 more
  • Tianjin, China
    Liu ningbo
May 7, 2021

Hepatic Impairment, Healthy Subjects Trial in Zhengzhou (Fluzoparib)

Recruiting
  • Hepatic Impairment
  • Healthy Subjects
  • Fluzoparib
  • Zhengzhou, Henan, China
    Henan Infectious Diseases Hospital
Jan 3, 2021

Pancreatic Cancer Trial in Shanghai (Fluzoparib)

Recruiting
  • Pancreatic Cancer
  • Fluzoparib
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Dec 30, 2020

Healthy Adult Subjects Trial in Qingdao (Fluzoparib)

Completed
  • Healthy Adult Subjects
  • Fluzoparib
  • Qingdao, Qingdao, China
    The affiliated hospital of QingDao university
Aug 19, 2020

Advanced Pancreatic Cancer Trial in Shanghai, Hangzhou (Fluzoparib, Fluzoparib , mFOLFIRINOX)

Recruiting
  • Advanced Pancreatic Cancer
  • Fluzoparib
  • +2 more
  • Shanghai, Shanghai, China
  • +1 more
Aug 9, 2020

Small Cell Lung Cancer Extensive Stage Trial in Tianjin (Fluzoparib, Apatinib)

Recruiting
  • Small Cell Lung Cancer Extensive Stage
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Dec 2, 2020

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation Trial in Shanghai (Fluzoparib;

Recruiting
  • Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
  • Fluzoparib; Apatinib
  • +2 more
  • Shanghai, China
    Jiangsu HengRui Medicine Co., Ltd.
Aug 6, 2020

Small Cell Lung Cancer Trial in Chengdu (Fluzoparib, temozolomide, SHR-1316)

Unknown status
  • Small Cell Lung Cancer
  • Fluzoparib
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Jun 19, 2020

Healthy Male Subjects Trial in Hangzhou (Fluzoparib, Rifampicin)

Completed
  • Healthy Male Subjects
  • Hangzhou, Zhejiang, China
    First Affiliated Hospital of Zhejiang University School of Medic
Feb 25, 2020

Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)

Not yet recruiting
  • Breast Neoplasm
  • +4 more
  • PIK3CA inhibitor
  • +12 more
  • (no location specified)
Oct 25, 2022

Metastatic Pancreatic Cancer Trial in China (Fluzoparib, Placebo)

Recruiting
  • Metastatic Pancreatic Cancer
  • Fluzoparib
  • Placebo
  • Hefei, Anhui, China
  • +23 more
Jan 7, 2021

Advanced Cancer Trial in Hunan (Fluzoparib, Fluconazole)

Completed
  • Advanced Cancer
  • Hunan, Hunan, China
    Early Cancer Research Center of Hunan Cancer Hospital
Dec 8, 2019

Breast Tumor, Breast Cancer, Breast Tumors Trial in Shanghai (Dalpiciclib, Pyrotinib, SHR-A1811)

Not yet recruiting
  • Breast Neoplasm
  • +9 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 13, 2022

Recurrent and Metastatic Gastric Cancer Trial in Beijing (Fluzoparib, Apatinib, Paclitaxel)

Unknown status
  • Recurrent and Metastatic Gastric Cancer
  • Fluzoparib
  • +2 more
  • Beijing, Beijing, China
    The Affiliated Hospital of Military Medical Sciences
Mar 5, 2017

Solid Tumor Trial in Changchun (Fluzoparib)

Completed
  • Solid Tumor
  • Fluzoparib
  • Changchun, Jilin, China
    the First Hosital of Jilin University
Feb 20, 2017